GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

GlaxoSmithKline Pakistan Cash Flow Statement

Financials in millions PKR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	10,025	6,536	533.95	2,463	5,354
Depreciation & Amortization	1,374	1,136	932.3	859.38	775.27
Loss (Gain) From Sale of Assets	-74.07	-21.88	-82.76	-124.62	-633.9
Asset Writedown & Restructuring Costs	42.01	18.39	6.01	18.02	15.54
Provision & Write-off of Bad Debts	21.51	1.76	160.34	89.7	42.74
Other Operating Activities	180.42	1,552	-703.15	-431.51	1,204
Change in Accounts Receivable	-2,279	471.58	395.71	-358.67	-154.15
Change in Inventory	-2,739	-365.39	-2,256	-3,363	-1,077
Change in Accounts Payable	557.26	-1,009	4,332	2,827	-36.69
Change in Other Net Operating Assets	1,555	-3,257	-1,386	-5,142	-512.05
Operating Cash Flow	8,664	5,058	1,884	-3,161	4,987
Operating Cash Flow Growth	71.30%	168.51%	-	-	-16.33%
Capital Expenditures	-2,583	-2,775	-1,649	-1,533	-1,304
Sale of Property, Plant & Equipment	275.65	134.32	212.95	244.47	777.27
Other Investing Activities	518.14	538.91	279.45	827.1	374.94
Investing Cash Flow	-1,789	-2,102	-1,157	-461.6	-151.56
Long-Term Debt Repaid	-54.31	-51.12	-25.59	-14.6	-11.46
Net Debt Issued (Repaid)	-54.31	-51.12	-25.59	-14.6	-11.46
Common Dividends Paid	-4,742	-1.76	-1,845	-375.03	-2,062
Financing Cash Flow	-4,796	-52.88	-1,871	-389.63	-2,073
Net Cash Flow	2,079	2,903	-1,144	-4,012	2,762
Free Cash Flow	6,081	2,282	234.56	-4,694	3,683
Free Cash Flow Growth	166.44%	873.04%	-	-	-20.69%
Free Cash Flow Margin	9.23%	3.73%	0.47%	-11.22%	10.05%
Free Cash Flow Per Share	19.09	7.17	0.74	-14.74	11.57
Cash Income Tax Paid	7,284	2,698	2,309	2,639	871.59
Levered Free Cash Flow	6,758	3,051	-1,126	-1,473	3,545
Unlevered Free Cash Flow	6,785	3,063	-1,122	-1,470	3,549
Change in Working Capital	-2,906	-4,160	1,085	-6,036	-1,780

Source: S&P Global Market Intelligence. Standard template. Financial Sources.